These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21490353)

  • 81. Antiviral therapy of herpes simplex and varicella-zoster virus infections.
    Wutzler P
    Intervirology; 1997; 40(5-6):343-56. PubMed ID: 9675639
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Guidance on management of asymptomatic neonates born to women with active genital herpes lesions.
    Kimberlin DW; Baley J; ;
    Pediatrics; 2013 Feb; 131(2):e635-46. PubMed ID: 23359576
    [TBL] [Abstract][Full Text] [Related]  

  • 83. ACOG practice bulletin: Clinical management guidelines for obstetrician-gynecologists, number 57, November 2004. Gynecologic herpes simplex virus infections.
    ACOG Committee on Practice Bulletins--Gynecology
    Obstet Gynecol; 2004 Nov; 104(5 Pt 1):1111-8. PubMed ID: 15516420
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Vertical transmission of genital herpes: prevention and treatment options.
    Jones CA
    Drugs; 2009; 69(4):421-34. PubMed ID: 19323586
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Recurrent genital herpes treatments and their impact on quality of life.
    Brentjens MH; Yeung-Yue KA; Lee PC; Tyring SK
    Pharmacoeconomics; 2003; 21(12):853-63. PubMed ID: 12908841
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Recent advances in management of genital herpes.
    Tétrault I; Boivin G
    Can Fam Physician; 2000 Aug; 46():1622-9. PubMed ID: 10955181
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model.
    Field HJ; Tewari D; Sutton D; Thackray AM
    Antimicrob Agents Chemother; 1995 May; 39(5):1114-9. PubMed ID: 7625798
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Cost effectiveness of newer antiviral agents for herpes zoster: is the evidence spotty?
    Smith KJ; Roberts MS
    J Infect Dis; 1998 Nov; 178 Suppl 1():S85-90. PubMed ID: 9852982
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Beyond efficacy: new issues for HSV antiviral therapy.
    Wald A
    Genitourin Med; 1997 Apr; 73(2):83-4. PubMed ID: 9215085
    [No Abstract]   [Full Text] [Related]  

  • 90. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV.
    Warren T; Harris J; Brennan CA
    Clin Infect Dis; 2004 Nov; 39 Suppl 5():S258-66. PubMed ID: 15494897
    [TBL] [Abstract][Full Text] [Related]  

  • 91. New drugs--reports of new drugs recently approved by the FDA. Valacyclovir.
    Shinkai I; Ohta Y
    Bioorg Med Chem; 1996 Jan; 4(1):1-2. PubMed ID: 8689229
    [No Abstract]   [Full Text] [Related]  

  • 92. Treatment modalities and medication recommended by health care professionals for treating recurrent herpes labialis.
    Raborn GW; Chan KS; Grace M
    J Am Dent Assoc; 2004 Jan; 135(1):48-54. PubMed ID: 14959874
    [TBL] [Abstract][Full Text] [Related]  

  • 93. A case series using famciclovir in stem cell transplant recipients with valacyclovir hypersensitivity reactions.
    Shah SA; Gulbis A; Wilhelm K
    J Oncol Pharm Pract; 2015 Aug; 21(4):305-9. PubMed ID: 24714130
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women.
    Andrews WW; Kimberlin DF; Whitley R; Cliver S; Ramsey PS; Deeter R
    Am J Obstet Gynecol; 2006 Mar; 194(3):774-81. PubMed ID: 16522412
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The use of antiviral medications in the treatment of herpes simplex virus infections of women.
    Baker DA
    Int J Fertil Womens Med; 1999; 44(5):227-33. PubMed ID: 10569451
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial.
    Caughey AB; Urato AC; Lurie P
    Obstet Gynecol; 2006 Dec; 108(6):1550; author reply 1550-2. PubMed ID: 17138792
    [No Abstract]   [Full Text] [Related]  

  • 97. Labeling updates to genital herpes drug.
    FDA Consum; 2003; 37(6):3. PubMed ID: 14983803
    [No Abstract]   [Full Text] [Related]  

  • 98. The comparative effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice.
    LeBlanc RA; Pesnicak L; Godleski M; Straus SE
    J Infect Dis; 1999 Sep; 180(3):594-9. PubMed ID: 10438344
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.
    Gupta R; Wald A; Krantz E; Selke S; Warren T; Vargas-Cortes M; Miller G; Corey L
    J Infect Dis; 2004 Oct; 190(8):1374-81. PubMed ID: 15378428
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency.
    Thackray AM; Field HJ
    J Infect Dis; 1996 Feb; 173(2):291-9. PubMed ID: 8568288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.